利奈唑胺治疗肺结核合并重症肺炎患者的临床疗效及安全性

Clinical Efficacy and Safety of Linezolid in the Treatment of Patients with Pulmonary Tuberculosis Complicated with Severe Pneumonia

目的探究利奈唑胺治疗肺结核合并重症肺炎患者的临床疗效及安全性。方法选取我院收治的肺结核合并重症肺炎患者108例,采用摸球法分为甲组(54例)和乙组(54例)。两组患者均给予常规治疗,甲组辅以利奈唑胺治疗,乙组辅以异烟肼片、乙胺丁醇、利福喷丁治疗,治疗2周后开展随访,比较两组患者临床疗效、不良反应发生率、并发症发生率、各临床症状缓解时间以及治疗后C反应蛋白、白细胞计数、白细胞介素4、肿瘤坏死因子α水平。结果甲组患者不良反应发生率5.56%低于乙组的9.26%,差异无统计学意义(P>0.05)。甲组患者并发症发生率3.70%低于乙组的18.52%(P<0.05)。甲组患者治疗总有效率96.30%高于乙组的75.93%(P<0.05)。甲组患者低热、气喘、咳嗽、呼吸不畅症状缓解时间均短于乙组(P<0.05)。治疗后,甲组患者C反应蛋白、白细胞计数、白细胞介素4、肿瘤坏死因子α水平均低于乙组,差异有统计学意义(P<0.05)。结论利奈唑胺治疗肺结核合并重症肺炎患者的临床疗效显著,可有效控制不良反应及并发症发生风险,安全性及有效性均处于较高水平。

Objective To explore the clinical efficacy and safety of linezolid in the treatment of patients with pulmonary tuberculosis complicated with severe pneumonia.Methods A total of 108 patients with pulmonary tuberculosis complicated with severe pneumonia admitted to our hospital were selected and divided into group A(54 cases)and group B(54 cases)using the ball method.Both groups of patients were given conventional treatment,group A was supplemented with linezolid treatment,and group B was supplemented with isoniazid tablets,ethambutol,and rifapentine treatment.Followup observation was carried out 2 weeks after treatment,to compare the clinical efficacy,incidence of adverse reactions,incidence of complications,time to relief of various clinical symptoms,and the level of C-reactive protein,white blood cell count,interleukin 4,tumor necrosis factor alpha after treatment of patients of two groups.Results The incidence of adverse reactions in group A was 5.56%,which was slightly lower than 9.26%of group B,the difference was not statistically significant(P>0.05).The complication rate in group A was 3.70%,which was lower than 18.52%of group B(P<0.05).The total effective rate of treatment in group A was 96.30%,which was higher than 75.93%of group B(P<0.05).The relief time of symptoms of group A patients with low fever,asthma,cough,and shortness of breath were relieved in a shorter time than group B(P<0.05).After treatment,the levels of C-reactive protein,white blood cell count,serum interleukin-4,and tumor necrosis factor alpha in group A were lower than those in group B,and the difference were statistically significant(P<0.05).Conclusion Linezolid has a significant clinical effect in the treatment of patients with pulmonary tuberculosis complicated with severe pneumonia.It can effectively control the risk of adverse reactions and complications,and its safety and effectiveness are at a high level.